Xenon Pharmaceuticals Q3 EPS $(1.11) Beats $(1.13) Estimate
Benzinga Newsdesk 6 hours ago
NewsEarningsEarnings Beats
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.13) by 1.77 percent. This is a 3.48 percent increase over losses of $(1.15) per share
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.13) by 1.77 percent. This is a 3.48 percent increase over losses of $(1.15) per share from the same period last year.